Table 3.
Active clinical trials of lipoplex-based delivery systems containing nucleic acids for cancer treatment.
| Lipid | Gene/Drug | Disease | Administration Route | Phase (Start Year) |
Sponsors | Identifier |
|---|---|---|---|---|---|---|
| n.r. | mRNA encoding human OX40L | Advanced/metastatic solid tumors or lymphoma | Intratumoral | I/II recruiting (2017) | ModernaTX, Inc. (Cambridge, MA, USA) | NCT03323398 |
| Lipo-MERIT | NY-ESO-1, MAGE-A3, and TPPE RNA | Melanoma | Intravenous | I recruiting (2015) | BioNTech SE (Mainz, Germany) | NCT02410733 |
| DOTAP:Chol | Pbi-shRNA™ EWS/FLI1 Type 1 | Ewing’s sarcoma. | Intravenous | I recruiting (2016) | Gradalis, Inc. (New York, NY, USA) | NCT02736565 |
| DOPC | EphA2 siRNA | Advanced Malignant Solid Neoplasm | Intravenous | I active (2012) | M.D. Anderson Cancer Center (Houston, TX, USA) | NCT01591356 |
| DOTAP:Chol | TUSC2 | Lung Cancer | Intravenous | I/II active (2011) | Genprex, Inc. (Houston, TX, USA) | NCT01455389 |
| DOTAP:DOPE | SGT-53 | Recurrent/refractory solid tumors in children | Intravenous | I active (2015) | SynerGene Therapeutics, Inc. (Houston, TX, USA) | NCT02354547 |
| DOTAP:DOPE | SGT-53 | Metastatic pancreatic cancer | Intravenous | II recruiting (2015) | SynerGene Therapeutics, Inc. (Houston, TX, USA) | NCT02340117 |
NY-ESO-1—New York-ESO 1; MAGE-A3—tyrosinase, Melanoma-associated antigen A3; TPTE—Transmembrane phosphatase with tensin homology; TUSC2—Tumor suppressor candidate 2; SGT-53—a complex of cationic liposome encapsulating a normal human wild type p53 cDNA sequence in a plasmid backbone; n.r.—not reported.